Under the terms of the deal, people with cystic fibrosis living in Wales who are aged 12 and over with two copies of the F508del mutation, or one copy of F508del and one copy of a 'minimal function mutation' will be eligible for Kaftrio.
The agreement also means patients with rare mutations, which fall outside of the scope of the EMA approval, will be able to benefit the range of treatments where they and their clinicians agree treatment is appropriate.
The announcement follows a similar deal in England and comes after a long-fought campaign for life-saving medicines by the Trust and the whole CF community.
David Ramsden, Chief Executive of the Cystic Fibrosis Trust, said: “News of a deal between the Welsh Government and Vertex Pharmaceuticals is fantastic. Kaftrio will now be available to people across Wales in the coming weeks and will truly save lives.
“While this is a great moment, we will not stop until everyone with cystic fibrosis across the UK can truly live a life unlimited.”
Rebecka Bow, whose daughter Sofia has CF, said: “This is life changing for us and for so many other people. To know that our daughter can now have a future is completely overwhelming. We're beyond happy.”
The Trust will continue to fight for everyone living with CF, regardless of their genotype. Donate now to support this vital work, and find out more about what licensing the triple therapy means for you.